Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AADC | Aromatic L-amino acid decarboxylase |
| AADCD | Aromatic L-amino acid decarboxylase deficiency |
| AAN | American Academy of Neurology |
| AAV | Adeno-associated virus |
| AAV1 | Adeno-associated virus serotype 1 |
| AAV2 | Adeno-associated virus serotype 2 |
| AAV5 | Adeno-associated virus serotype 5 |
| AAV9 | Adeno-associated virus serotype 9 |
| ACP | Advance care planning |
| adj-R2 | Adjusted R-squared |
| ADM | Antidopaminergic medication |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| ALT | Alanine aminotransferase |
| ANOVA | Analysis of variance |
| anti-HBc | Hepatitis B core antibody |
| anti-HCV | Hepatitis C virus antibody |
| AOHD, AoHD | Adult-onset Huntington's disease |
| APD | Antipsychotic drug |
| AS | Advanced stage |
| ASNSD1 | Asparagine synthetase domain containing 1 |
| ASO | Antisense oligonucleotide |
| ATIMP | Advanced therapy investigational medicinal product |
| BLA | Biologics License Application |
| C-SSRS | Columbia-Suicide Severity Rating Scale |
| CAG | Cytosine-adenine-guanine trinucleotide repeat |
| CAP | CAG-age product |
| CAP100 | CAG-age product scaled to 100 at the expected age of onset |
| CAT | Committee for Advanced Therapies (European Medicines Agency) |
| CBER | Center for Biologics Evaluation and Research (US Food and Drug Administration) |
| CED | Convection-enhanced delivery |
| CEPAC | Comparative Effectiveness Public Advisory Council |
| CGI-S | Clinical Global Impression of Severity |
| CHDI | Cure Huntington's Disease Initiative |
| CI | Confidence interval |
| cis-eQTL | Cis-acting expression quantitative trait locus |
| CMC | Chemistry, manufacturing, and controls |
| CMS | Centers for Medicare & Medicaid Services |
| CN | Caudate nucleus |
| CNS | Central nervous system |
| COE | Center of Excellence |
| COHORT | Cooperative Huntington's Observational Research Trial |
| COVID-19 | Coronavirus disease 2019 |
| CRD | Centre for Rare Disorders (Oslo University Hospital) |
| CSF | Cerebrospinal fluid |
| CSHL | Cold Spring Harbor Laboratory |
| CSI | Caregiver Strain Index |
| CTIS | Clinical Trials Information System (European Union) |
| cUDHRS | Composite Unified Huntington's Disease Rating Scale (spelling in a quoted source) |
| cUHDRS | Composite Unified Huntington's Disease Rating Scale |
| CYP2D6 | Cytochrome P450 2D6 |
| DARPP-32 | Dopamine- and cAMP-regulated phosphoprotein of 32 kDa |
| DCL | Diagnostic confidence level |
| DMD | Duchenne muscular dystrophy |
| dMRI | Diffusion magnetic resonance imaging |
| DMT | Disease-modifying treatment |
| DNA | Deoxyribonucleic acid |
| DSMB | Data Safety Monitoring Board |
| ECG | Electrocardiogram |
| eCRF | Electronic case record form |
| EHDN | European Huntington's Disease Network |
| EM | Extensive metabolizer |
| EMA | European Medicines Agency |
| EQ-5D | EuroQol 5-dimension questionnaire |
| EQ-5D-3L | EuroQol 5-dimension questionnaire, 3-level version |
| EQ-5D-5L | EuroQol 5-dimension questionnaire, 5-level version |
| ES | Early stage |
| EU | European Union |
| EV | Extracellular vesicle |
| evLY | Equal value of life year |
| FAN1 | FANCD2 and FANCI associated nuclease 1 |
| FDA | US Food and Drug Administration |
| FHD | First human dose |
| FIH | First-in-human |
| First-HD | First Time Use of SD-809 in Huntington Disease trial |
| FL | Full-length |
| FOCP | Female of childbearing potential |
| GC, gc | Genetic counseling (GC); genome copies (gc) |
| GCIT | Gene-based, Cellular and other Innovative Therapies (Aetna network) |
| GENEROUS | Generating Cost Reductions for U.S. Medicaid (Model) |
| GFAP | Glial fibrillary acidic protein |
| GFP | Green fluorescent protein |
| GINA | Genetic Information Nondiscrimination Act |
| GMP | Good manufacturing practice |
| GP | General population |
| GP-CP | General population care partners |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| GTx | Gene therapy |
| GWA | Genome-wide association |
| GWAS | Genome-wide association study |
| H-QoL-I | Huntington Quality of Life Instrument |
| HADS | Hospital Anxiety and Depression Scale |
| HBPB | Health Benefit Price Benchmark |
| HBsAg | Hepatitis B surface antigen |
| HCV | Hepatitis C virus |
| HD | Huntington's disease |
| HD-CAB | Huntington's Disease Cognitive Assessment Battery |
| HD-CP | Huntington's disease care partners |
| HD-CSF | Huntington's Disease Cerebrospinal Fluid study |
| HD-ISS | Huntington's Disease Integrated Staging System |
| HDBOI | Huntington's Disease Burden of Illness study |
| HDGEC | Huntington's disease gene-expansion carrier |
| HDQLIFE | Huntington Disease Health-related Quality of Life measurement system |
| HDSA | Huntington's Disease Society of America |
| HE | Highly expanded (CAG repeat subgroup) |
| HIV | Human immunodeficiency virus |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| HRU | Healthcare resource utilization |
| HSG | Huntington Study Group |
| HSUV | Health state utility value |
| HTT | Huntingtin gene or protein |
| HTT1a | Truncated huntingtin transcript containing exon 1 and part of intron 1 |
| HTTexon1 | Huntingtin exon 1 protein |
| Iba1 | Ionized calcium-binding adapter molecule 1 |
| IC | Informal caregiver |
| ICC2,1 | Intraclass correlation coefficient, two-way random-effects model, single measure |
| ICER | Institute for Clinical and Economic Review; incremental cost-effectiveness ratio |
| iDMC | Independent Data Monitoring Committee |
| IHD | Individuals with Huntington's disease |
| IMP | Investigational medicinal product |
| IND | Investigational New Drug application |
| IPD | Individuals with Parkinson's disease |
| IPiN | Institute of Psychiatry and Neurology, Warsaw (Instytut Psychiatrii i Neurologii) |
| IQR | Interquartile range |
| IS | Independence Scale |
| ISS-2, ISS-3 | Huntington's Disease Integrated Staging System stage 2, stage 3 |
| IVF | In vitro fertilization |
| JHD | Juvenile Huntington's disease |
| JoHD | Juvenile-onset Huntington's disease |
| KI | Knock-in |
| KM | Kaplan-Meier |
| LDL | Low-density lipoprotein |
| LE | Low expansion (CAG repeat subgroup) |
| LIG1 | DNA ligase 1 |
| LoHD | Late-onset Huntington's disease |
| LS | Least squares |
| LSM | Least squares mean |
| LTC | Long-term care |
| LTFU | Long-term follow-up |
| MA | Marketing authorisation |
| MAA | Marketing Authorisation Application |
| MBP | Medicaid Best Price |
| MCSI | Modified Caregiver Strain Index |
| MDS | International Parkinson and Movement Disorder Society; movement disorders specialist |
| MDT | Multidisciplinary team |
| mg | Milligram |
| MHRA | Medicines and Healthcare products Regulatory Agency (United Kingdom) |
| mHTT | Mutant huntingtin protein |
| miHTT | Engineered microRNA targeting the huntingtin exon 1 sequence |
| miRNA | MicroRNA |
| mL | Milliliter |
| MLH1 | MutL homolog 1 |
| MMR | DNA mismatch repair |
| MMRM | Mixed-effects model for repeated measures |
| MoCA | Montreal Cognitive Assessment |
| MRI | Magnetic resonance imaging |
| mRNA | Messenger RNA |
| MRS | Magnetic resonance spectroscopy |
| MS | Mid stage |
| MS-DRG | Medicare Severity Diagnosis Related Group |
| MSH3 | MutS homolog 3 |
| mtHTT | Mutant huntingtin |
| NAb | Neutralizing antibody |
| NCDR | Norwegian Cause of Death Registry |
| NeuN | Neuronal nuclei (neuron-specific nuclear protein) |
| Neuro-QoL, NeuroQoL | Quality of Life in Neurological Disorders measurement system |
| NfL | Neurofilament light chain |
| NHP | Nonhuman primate |
| NHS | National Health Service |
| OBA | Outcomes-based agreement |
| PBA | Problem Behaviors Assessment |
| PC | Palliative care |
| PCA | Principal component analysis |
| PCP | Primary care physician |
| PD-CP | Parkinson's disease care partners |
| PDS | Periodic dataset (Enroll-HD) |
| PDUFA | Prescription Drug User Fee Act |
| PEG | Percutaneous endoscopic gastrostomy |
| PFD | Prefunctional decline |
| PGIC | Patient Global Impression of Change |
| PHQ-9 | Patient Health Questionnaire-9 |
| PI | Principal investigator |
| PIN | Prognostic Index Normed |
| PM | Poor metabolizer |
| PMPM | Per member per month |
| PMS1 | PMS1 homolog 1, mismatch repair system component (postmeiotic segregation increased 1) |
| PMS2 | PMS1 homolog 2, mismatch repair system component (postmeiotic segregation increased 2) |
| PoC | Proof of concept |
| PPIE-C | Patient Public Involvement Engagement-Caregiver questionnaire |
| PPIE-P | Patient Public Involvement Engagement-Patient questionnaire |
| PPPM | Per patient per month |
| PPQ | Process Performance Qualification |
| PREDICT-HD | Neurobiological Predictors of Huntington's Disease study |
| preHD | Premanifest Huntington's disease |
| preHD-A | Premanifest Huntington's disease group A (further from predicted onset) |
| preHD-B | Premanifest Huntington's disease group B (closer to predicted onset) |
| pri-miRNA | Primary microRNA transcript |
| PRIME | Priority Medicines (European Medicines Agency scheme) |
| PROMIS | Patient-Reported Outcomes Measurement Information System |
| PROOF-HD | Pridopidine Outcome on Function in Huntington Disease trial |
| PS | Propensity score |
| PSA | Probabilistic sensitivity analysis |
| PSM | Propensity score-matched |
| PT | Prothrombin time |
| PTT | Partial thromboplastin time |
| PwHB | People with hemophilia B |
| PwHD | People with Huntington's disease |
| PY | Person-years |
| Q-Motor | Quantitative Motor testing |
| Q1, Q3 | First quarter, third quarter |
| QALY | Quality-adjusted life year |
| QoL | Quality of life |
| qPCR | Quantitative polymerase chain reaction |
| rAAV5 | Recombinant adeno-associated virus serotype 5 |
| RCT | Randomized controlled trial |
| RMAT | Regenerative Medicine Advanced Therapy |
| RNA | Ribonucleic acid |
| RNAi | RNA interference |
| S/N | Signal-to-noise |
| S1R | Sigma-1 receptor |
| SAE | Serious adverse event |
| SAP | Statistical analysis plan |
| SCA1 | Spinocerebellar ataxia type 1 |
| SCA3 | Spinocerebellar ataxia type 3 |
| SD | Standard deviation |
| SDMT | Symbol Digit Modalities Test |
| SE | Standard error |
| SEC | US Securities and Exchange Commission |
| SF | Shoulson and Fahn (staging system) |
| SF-36v1 | 36-Item Short Form Health Survey, version 1 |
| SF-6D | Short-Form 6-Dimension |
| SF1, SF2 | Shoulson and Fahn stage 1, stage 2 |
| SMA | Spinal muscular atrophy |
| SMDT | Symbol Digit Modalities Test (spelling in a quoted source) |
| SNF | Skilled nursing facility |
| SNP | Single nucleotide polymorphism |
| SNRI | Serotonin-norepinephrine reuptake inhibitor |
| SoC | Standard of care |
| SPN | Striatal projection neuron |
| SSRI | Selective serotonin reuptake inhibitor |
| SST | Single or short-term therapy |
| STB | Suicidal thoughts and behavior |
| SUSAR | Suspected unexpected serious adverse reaction |
| SWR | Stroop Word Reading |
| SWRT | Stroop Word Reading Test |
| TBZ | Tetrabenazine |
| TEAE | Treatment-emergent adverse event |
| TFC | Total Functional Capacity |
| tgHD | Transgenic Huntington's disease (minipig model) |
| TMS | Total Motor Score |
| tNAA | Total N-acetylaspartate |
| TTO | Time trade-off |
| UHDRS | Unified Huntington's Disease Rating Scale |
| UK | United Kingdom |
| ULN | Upper limit of normal |
| US, USA | United States |
| USD | US dollars |
| VCU | Virginia Commonwealth University |
| vg, VG | Vector genomes |
| VMAT, VMAT2 | Vesicular monoamine transporter 2 |
| WAC | Wholesale acquisition cost |
| WHO | World Health Organization |
| WM | White matter |
| wtHTT | Wild-type huntingtin |
| WTP | Willingness to pay |
| XR | Extended-release |
| Y1 to Y4 | Year 1 to year 4 |
| YKL-40 | Chitinase-3-like protein 1 |